Egrifta (Tesamorelin) Medicare Advantage Coverage

Why Medicare Advantage Plans Rarely Cover Egrifta

Medicare Advantage (MA) plans build their Part D formularies around FDA-approved indications. The FDA approved tesamorelin in November 2010 solely for reducing excess abdominal fat in HIV-infected patients with lipodystrophy 1. This narrow label creates the primary coverage barrier for the broader patient population seeking tesamorelin for body composition or growth-hormone-related goals.

MA plans use step-therapy protocols and quantity limits even for HIV-positive enrollees. A 2023 analysis of Medicare Part D formulary files found that fewer than 12% of standalone Part D plans listed tesamorelin on any tier 2. Plans that do include it typically place Egrifta on Tier 5 (specialty) with cost-sharing between 25% and 33% after the deductible phase. For a $3,500 monthly drug, that translates to $875 to $1,155 out-of-pocket per fill before catastrophic coverage begins.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D (effective 2025) helps once a patient reaches the catastrophic phase, but getting past prior authorization remains the first obstacle 3.

The Prior Authorization Process for Tesamorelin Under Medicare

Prior authorization (PA) for Egrifta requires clinical documentation confirming HIV seropositivity, evidence of lipodystrophy (typically CT or DEXA showing elevated visceral adipose tissue), and failure of lifestyle interventions. CMS guidance allows MA plans to require chart notes showing at least 3 months of diet and exercise counseling before approving injectable therapies for body composition 4.

Most plans require the prescribing physician to submit:

• Confirmed HIV-1 diagnosis with viral load and CD4 documentation
• Imaging showing visceral adipose tissue accumulation (waist CT at L4-L5 or trunk DEXA)
• Documentation that antiretroviral therapy is stable for at least 6 months
• Prior trial of metformin or lifestyle intervention for truncal adiposity

Turnaround time for standard PA decisions is 72 hours under CMS rules, with a 24-hour expedited window available if the physician certifies clinical urgency 4. Denials are common. The overall Part D PA denial rate exceeded 8% across all drug classes in 2022 according to CMS data, and specialty biologics face higher rejection rates 5.

What to Do After a Medicare Advantage Denial

A denied PA is not the end. Medicare Advantage enrollees have a structured five-level appeal process. The first two levels (plan reconsideration and Independent Review Entity review) resolve 60% of overturned decisions 4.

For the coverage determination request, include peer-reviewed evidence showing clinical benefit. The LIPO-010 trial (N=412) demonstrated that tesamorelin 2 mg daily reduced visceral adipose tissue by 18% versus placebo at 26 weeks, with concurrent improvements in trunk fat and patient-reported body image scores 6. A follow-up extension study showed that benefits reversed within 26 weeks of discontinuation, which plans sometimes cite to argue the therapy lacks durable benefit 7.

Pair trial data with the 2014 Endocrine Society clinical practice guideline on GH-releasing peptides, which acknowledges tesamorelin's role in HIV lipodystrophy management as a targeted therapy distinct from exogenous GH 8.

If denied at the plan level, file with the Independent Review Entity (IRE) within 60 days. The IRE overturns approximately 75% of Part D coverage denials that reach it, per the Medicare Payment Advisory Commission's 2023 report to Congress 9.

Off-Label Use and Coverage Limitations

Patients without HIV who seek tesamorelin for visceral fat reduction, growth hormone pulse optimization, or metabolic health face a harder path. Medicare does not cover off-label use unless the indication is supported by one of the recognized compendia (AHFS Drug Information, DrugDex, or Clinical Pharmacology) 10.

Tesamorelin does have emerging data outside its HIV indication. A 2019 randomized trial (N=61) in non-HIV patients with NAFLD showed that tesamorelin reduced hepatic fat fraction by 37% versus an increase of 7% with placebo over 12 months 11. Another trial published in The Lancet HIV (N=31) confirmed persistent visceral fat reduction with long-term use but did not generate a label expansion 12.

These studies remain insufficient for compendia listing. No compendium currently supports off-label tesamorelin for non-HIV metabolic indications, making Medicare coverage for this population functionally impossible through standard channels as of 2026.

The Manufacturer Assistance Program

Theratechnologies operates the Egrifta SV Complete program for eligible patients. The program offers:

• Co-pay assistance cards reducing out-of-pocket costs to as low as $0 for commercially insured patients
• A bridge program providing up to 90 days of free medication during insurance transitions
• Nurse support for injection training and adherence

The critical limitation: co-pay assistance programs cannot legally be used by Medicare beneficiaries. The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits manufacturer co-pay cards for patients enrolled in any federal healthcare program, including Medicare Advantage 13. Medicare patients must use independent charitable patient assistance foundations instead, and availability fluctuates based on funding cycles.

The Patient Access Network (PAN) Foundation and HealthWell Foundation have intermittently offered funds for HIV-associated conditions, though neither currently lists an open Egrifta-specific fund as of early 2026. Patients should check panfoundation.org and healthwellfoundation.org monthly, as funds reopen without predictable schedules.

Compounded Tesamorelin: The $350 Alternative

Since tesamorelin's active pharmaceutical ingredient is available through FDA-registered 503B outsourcing facilities, compounded versions cost roughly one-tenth of brand Egrifta. Average pricing from 503B pharmacies ranges from $300 to $400 per month for a 2 mg daily protocol 14.

Key considerations for compounded tesamorelin:

Regulatory status. The FDA permits 503B outsourcing facilities to compound copies of commercially available drugs, but these products are not FDA-approved and do not undergo the same bioequivalence testing as generic medications 14. Patients should verify their pharmacy appears on the FDA's registered outsourcing facility list.

Purity and potency. Unlike brand Egrifta SV, which uses a proprietary lyophilized formulation with documented 93% bioavailability, compounded peptides may vary in reconstitution stability. A 2021 FDA inspection cycle found that 28% of 503B facilities received Form 483 observations related to sterility or potency issues 15.

Medicare payment. Medicare Part D does not cover compounded medications in most circumstances. Compounded drugs dispensed by retail pharmacies are excluded from Part D coverage unless they meet specific criteria under 42 CFR § 423.100. This means compounded tesamorelin is virtually always a cash-pay expense for Medicare beneficiaries 16.

Cost Comparison: Brand vs. Compounded vs. Covered

The financial calculus depends on insurance status and HIV diagnosis:

For an HIV-positive Medicare Advantage enrollee who obtains PA approval, the annual out-of-pocket maximum under the $2,000 Part D cap means brand Egrifta costs approximately $2,000/year after reaching catastrophic coverage 3. The first few months carry higher cost-sharing until the cap is met.

For a non-HIV patient paying cash for brand Egrifta: $42,000/year. That same patient using compounded tesamorelin: approximately $4,200/year. The 90% cost reduction explains why compounded peptides dominate the non-HIV tesamorelin market despite regulatory uncertainty.

For commercially insured patients with an HIV diagnosis, the Theratechnologies co-pay card can reduce monthly costs to $0, making brand the obvious choice when insurance covers the drug and the manufacturer absorbs remaining cost-sharing.

Strategies to Reduce Tesamorelin Costs in 2026

Several approaches exist beyond standard insurance coverage:

Extra Help (Low-Income Subsidy). Medicare beneficiaries with income below 150% of the federal poverty level may qualify for Extra Help, which limits Part D cost-sharing to $4.50 for generics and $11.20 for brand-name drugs in 2026 17. If tesamorelin is on the plan's formulary, this subsidy dramatically reduces the financial burden.

State Pharmaceutical Assistance Programs (SPAPs). Several states operate programs that wrap around Medicare Part D, covering co-pays or providing supplemental drug benefits. New York's EPIC program, for example, covers cost-sharing for enrollees meeting income thresholds 18.

Ryan White HIV/AIDS Program. For HIV-positive patients, the Health Resources and Services Administration's Ryan White program and AIDS Drug Assistance Programs (ADAPs) in each state may cover tesamorelin when Medicare leaves a coverage gap 19.

Clinical trials. The ongoing TRIUMPH trial (NCT04451291) and similar studies evaluating tesamorelin for NAFLD/MASLD may provide access to free study drug for patients meeting inclusion criteria 20.

Switching Medicare Advantage Plans for Better Coverage

MA plan formularies change annually. During the Annual Enrollment Period (October 15 through December 7), beneficiaries can switch to a plan with more favorable tesamorelin coverage. The Medicare Plan Finder tool at medicare.gov allows searching by specific drug to identify plans covering Egrifta in your service area.

Before switching, verify:

• Whether the plan places Egrifta on Tier 4 vs. Tier 5 (cost-sharing differs significantly)
• Whether the plan's specialty pharmacy network includes your preferred pharmacy
• The plan's specific PA criteria, which vary across insurers like UnitedHealthcare, Humana, Aetna, and Cigna MA products

Special Enrollment Periods may also apply for beneficiaries who lose creditable coverage, move service areas, or qualify for Extra Help 17.

The Future of Tesamorelin Access

Theratechnologies' composition-of-matter patents on tesamorelin have expired, but method-of-use patents and the REMS-like distribution restrictions continue limiting generic entry. No ANDA for generic tesamorelin has been approved by the FDA as of May 2026. The 505(b)(2) pathway remains a potential route for competitors, but no public filings indicate imminent generic launches 1.

If generic tesamorelin enters the market, Medicare Part D coverage would likely expand as plan sponsors add it to formularies at lower tiers. Until then, the combination of narrow FDA labeling, specialty-tier placement, and federal restrictions on manufacturer co-pay assistance keeps Egrifta financially inaccessible for most Medicare Advantage enrollees without an HIV diagnosis.